CD4+CD25highCD127low Regulatory T Cells in Peripheral Blood Are Not an Independent Factor for Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation

Table 1

Patient characteristics and transplantation details.

	Patients (𝑛=84)
Age in years (median (range))	46 (19–67)
Gender: male/female	50/34
Diagnosis:
AML/ALL/MDS	24/11/9
CML/OMF	7/3
CLL/NHL/MM	5/16/6
AA	3
Pretransplant conditioning:
Myeloablative regimens:	46
12 Gy TBI-cyclophosphamide/12 Gy TBI-etoposide	13/3
Busulphan-cyclophosphamide	8
8 Gy TBI-fludarabine/melphalan-fludarabine	4/16
Other	2
RIC regimens:	38
Fludarabine-cyclophosphamide/fludarabine-busulphan/fludarabine-cyclophosphamide-busulphan	9/3/7
2 Gy-fludarabine	13
Other	6
Donor type: sibling/unrelated	38/46
Stem cell source: bone marrow/peripheral stem cells	2/82
HLA matching (10 antigens): match/mismatch	60/24
CMV serostatus of recipient and donor: both negative/other	22/62
Gender match: match/mismatch	45/39
Blood group match: match/mismatch	47/37
Time after transplantation in months (median (range))	18 (5–120)

CML: chronic myeloid leukaemia; AML: acute myeloid leukaemia; ALL: acute lymphoid leukaemia; NHL: non-Hodgkin’s lymphoma; OMF: osteomyelofibrosis; MM: multiple myeloma; CLL: chronic lymphatic leukaemia; MDS: myelodysplastic syndrome; AA: aplastic anaemia; RIC: reduced intensity conditioning; CMV: cytomegalovirus; TBI: total body irradiation; HLA: human leucocyte antigen.